Search global stocks & ETFs...Ctrl K
Learn Mode
GH
Stock Profile
07-30
Recommended Metric
Score Card
Explore Scores Tab
2.70
Average
Valuation Score
Key Score
1.00
Very Bad
Management
1.00
Very Bad
Growth
3.00
Average
Profitability
3.00
Average
Fin. Health
1.00
Very Bad
Dividends
--
--
Analyst
5.00
Very Good
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending Jun 28, 2027
Current
$155.87
Baseline
High
$199.50
▲
27.99%
Avg
$149.11
▼
-4.34%
Low
$93.33
▼
-40.12%
Analyst Ratings based on 35 Analysts
Strong Buy
1543%
Buy
1851%
Hold
206%
Sell
000%
Strong Sell
000%
Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 2,490 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.Read More